Evidence map›Paper›PMID 35222843›Full record

ArticleComputational and structural biotechnology journal2022

Identifying individualized risk subpathways reveals pan-cancer molecular classification based on multi-omics data.

Yanjun Xu, Jingwen Wang, Feng Li, Chunlong Zhang, Xuan Zheng, Yang Cao, Desi Shang, Congxue Hu, Yingqi Xu, Wanqi Mi and 3 more

Abstract read
In one paragraph

Article in Computational and structural biotechnology journal, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. The cross-talk between GSK-3β, RKIP, and PTEN as potential targets for therapeutic implications in cancer: a comprehensive insight.Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques · 2026
    Review
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Yanjun XuCollege of Bioinformatics Science and Technology, Harbin Medical University, Harbin, China.
Jingwen WangCollege of Bioinformatics Science and Technology, Harbin Medical University, Harbin, China.
Feng LiCollege of Bioinformatics Science and Technology, Harbin Medical University, Harbin, China.
Chunlong ZhangCollege of Bioinformatics Science and Technology, Harbin Medical University, Harbin, China.
Xuan ZhengCollege of Bioinformatics Science and Technology, Harbin Medical University, Harbin, China.
Yang CaoHarbin Medical University Cancer Hospital, Harbin, China.
Desi ShangCollege of Bioinformatics Science and Technology, Harbin Medical University, Harbin, China.
Congxue HuCollege of Bioinformatics Science and Technology, Harbin Medical University, Harbin, China.
Yingqi XuCollege of Bioinformatics Science and Technology, Harbin Medical University, Harbin, China.
Wanqi MiCollege of Bioinformatics Science and Technology, Harbin Medical University, Harbin, China.
Xia LiCollege of Bioinformatics Science and Technology, Harbin Medical University, Harbin, China.
Yan CaoHarbin Medical University Cancer Hospital, Harbin, China.
Yunpeng ZhangCollege of Bioinformatics Science and Technology, Harbin Medical University, Harbin, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cancer is a highly heterogeneous disease with different functional disorders among individuals. The initiation and progression of cancer is usually related to dysregulation of local regions within pathways. Identification of individualized risk pathways is crucial for revealing the mechanisms of tumorigenesis and heterogeneity. However, approach that focused on mining patient-specific risk subpathway regions is still lacking. Here, we developed an individualized cancer risk subpathway identification method that was referred as InCRiS by integrating multi-omics data. Then, the method was applied to nearly 3000 samples across 9 TCGA cancer types and its robustness and reliability were evaluated. Dissecting dysregulated subpathways in these tumor samples revealed several key regions which may play oncogenic roles in cancer. The construction of risk subpathway dysregulation profile of pan-cancers revealed 11 pan-cancer molecular classification (InCRiS subtypes) with significantly different clinical outcomes. Moreover, subpathway regions that tend to be disordered in individuals of specific subtypes were examined for understanding the pathogenesis of tumor and some key genes such as CTNNB1, EP300 and PRKDC were nominated in different subtypes. In summary, the proposed method and resulting data presented useful resources to study the mechanism of tumor heterogeneity and to discovery novel therapeutic targets for precise treatment of cancer.

Indexed as

Individualized risk subpathwayMulti-omicsPan-cancerPathway analysis

Identifiers

PMID35222843
PMCPMC8842010

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.